Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cancer Immunotherapy Sees Setback With Failure Of Cell Genesys’ GVAX

This article was originally published in The Pink Sheet Daily

Executive Summary

Cell Genesys will cut 75 percent of its workforce and explore strategic alternatives after halting development of the prostate cancer vaccine.

You may also be interested in...



Roche’s Push In Cancer Immunotherapy: An Interview With New Exec Hy Levitsky

“Cancer immunology will play a far greater role than it ever has within the [Roche Pharma Research and Early Development Organization] and we hope there will be synergies we can exploit with other treatment modalities under development at Roche,” Levitsky says.

With Strong Safety Data For LibiGel, BioSante Raises $11.1 Million

Down to about $6 million at the end of the second quarter, the sexual health products firm uses a merger and private placement to significantly upgrade its cash position.

With Strong Safety Data For LibiGel, BioSante Raises $11.1 Million

Down to about $6 million at the end of the second quarter, the sexual health products firm uses a merger and private placement to significantly upgrade its cash position.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS066887

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel